Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System

Table 5

All concomitant drugs and concomitant antidiabetic drugs received by FG patients under SGLT2 inhibitor therapy.

All concomitant drugs	(%)	Concomitant antidiabetic drugs	(%)
Cardiovascular system	355 (34.84%)	Metformin	110 (34.81%)
Endocrine system	329 (32.29%)	Insulin	98 (31.01%)
Nervous system	61 (5.99%)	Dipeptidyl peptidase-4 inhibitors	54 (17.09%)
Gastrointestinal system	60 (5.89%)	Sulfonylurea	37 (11.71%)
Blood and nutrition	48 (4.71%)	Thiazolidinediones	8 (2.53%)
Anti-inflammatory and analgesic	36 (3.53%)	Combination therapy	5 (1.58%)
Respiratory system	29 (2.85%)	Meglitinides	2 (0.63%)
Infection	22 (2.16%)	Alpha-glucosidase inhibitors	1 (0.32%)
Immune system and malignant disease	21 (2.06%)	Other	1 (0.32%)
Controlled drug	18 (1.77%)	Total	316
Genitourinary system	18 (1.77%)
Others	17 (1.67%)
Skin	4 (0.39%)
Musculoskeletal system	1 (0.10%)
Total	1019